Therapeutic effect of Intra-Tympanic Dexamethasone-Hyaluronic Acid Combination in Sudden Sensorineural Hearing Loss
- PMID: 28955673
- PMCID: PMC5610373
Therapeutic effect of Intra-Tympanic Dexamethasone-Hyaluronic Acid Combination in Sudden Sensorineural Hearing Loss
Abstract
Introduction: Hearing loss is fairly a common disorder which is usually treated with corticosteroids via systemic administration and/or intra-tympanic injection. This study aimed to compare the effectiveness of intra-tympanic injections of dexamethasone with its combination with hyaluronic acid in patients with sudden sensorineural hearing loss.
Materials and methods: In this clinical trial, 40 patients were randomly assigned to two groups; in the first group, 20 patients received 2.4 mg intra-tympanic dexamethasone, while in the second group patients received injections of 2.4 mg of dexamethasone plus 2 mg of hyaluronic acid in combination. Patients in both groups were injected every other day to a total of three injections. The hearing status of patients was evaluated by pure tone audiometry (bone conduction threshold) before and 2 weeks after the intervention.
Results: Assessment of hearing threshold before and after treatment in the two groups showed a significant difference between hearing thresholds at frequencies of 4,000 to 8,000 Hz (P<0.001). The difference at other frequencies was not meaningful; however, in general, we found a better therapeutic effect in patients who received the combination of dexamethasone and hyaluronic acid.
Conclusion: A combination of dexamethasone and hyaluronic acid in patients with sudden sensorineural hearing loss may be more effective than dexamethasone alone. Because hyaluronic acid lacks certain side effects, and also makes it possible to reduce the steroid dose, we recommend the use of this combination in the treatment of patients with sudden sensorineural hearing loss.
Keywords: Dexamethasone; Hyaluronic acid; Intra tympanic injection; Sudden sensorineural hearing loss.
Figures
Similar articles
-
Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.Eur Arch Otorhinolaryngol. 2005 Feb;262(2):131-4. doi: 10.1007/s00405-004-0772-6. Epub 2004 Apr 29. Eur Arch Otorhinolaryngol. 2005. PMID: 15747106 Clinical Trial.
-
Intratympanic dexamethasone and hyaluronic acid in patients with low-frequency and Ménière's-associated sudden sensorineural hearing loss.Otol Neurotol. 2005 Sep;26(5):890-5. doi: 10.1097/01.mao.0000185050.69394.48. Otol Neurotol. 2005. PMID: 16151334
-
Intratympanic dexamethasone/hyaluronic acid mix as an adjunct to intravenous steroid and vasoactive treatment in patients with severe idiopathic sudden sensorineural hearing loss.Otol Neurotol. 2011 Jul;32(5):756-60. doi: 10.1097/MAO.0b013e31821a3fc3. Otol Neurotol. 2011. PMID: 21646933
-
Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.Laryngoscope. 2007 Jan;117(1):3-15. doi: 10.1097/01.mlg.0000245058.11866.15. Laryngoscope. 2007. PMID: 17202923 Review.
-
Intratympanic injection of dexamethasone for treatment of tinnitus in patients with sudden sensorineural hearing loss.Audiol Res. 2012 Jan 9;2(1):e2. doi: 10.4081/audiores.2011.e2. eCollection 2012 Jan 9. Audiol Res. 2012. PMID: 26557331 Free PMC article. Review.
Cited by
-
In vitro characterization of novel hyaluronan-antioxidant conjugates as potential topical therapeutics against hearing loss.Front Pharmacol. 2024 Feb 28;15:1355279. doi: 10.3389/fphar.2024.1355279. eCollection 2024. Front Pharmacol. 2024. PMID: 38482050 Free PMC article.
-
Comparison of hearing outcomes in stapedotomy with fat and Hyaluronic acid gel as a sealing material: a prospective double-blind randomized clinical trial.Eur Arch Otorhinolaryngol. 2021 Nov;278(11):4279-4287. doi: 10.1007/s00405-020-06554-y. Epub 2021 Jan 11. Eur Arch Otorhinolaryngol. 2021. PMID: 33426570 Clinical Trial.
-
Hyaluronic acid-ibuprofen conjugation: a novel ototherapeutic approach protecting inner ear cells from inflammation-mediated damage.Front Pharmacol. 2024 Feb 15;15:1355283. doi: 10.3389/fphar.2024.1355283. eCollection 2024. Front Pharmacol. 2024. PMID: 38425644 Free PMC article.
-
Intratympanic Injection of Edaravone for Idiopathic Sudden Sensorineural Hearing Loss with Profound Hearing Loss.J Int Adv Otol. 2025 May 22;21(3):1-7. doi: 10.5152/iao.2025.251875. J Int Adv Otol. 2025. PMID: 40415448 Free PMC article.
-
Intratympanic corticosteroids for sudden sensorineural hearing loss.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD008080. doi: 10.1002/14651858.CD008080.pub2. Cochrane Database Syst Rev. 2022. PMID: 35867413 Free PMC article.
References
-
- Tüzemen G, Kasapoğlu F, Hızalan İ, Akyıldız MY. The importance of the first three days and other diagnostic indicators in sudden hearing loss. Kuak Burun Bogaz Ihtis Derg. 2016;26(6):333–41. - PubMed
-
- Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss A systematic review. Arch Otolaryngol Head Neck Surg. 2007;133(6):573–81. - PubMed
-
- Mohsen Rajati. Mahmoud Reza Azarpajooh. Studying VEMP in Sudden Sensorineural Hearing Loss. Iran J Otorhinolaryngol. 2011;2364:64.
-
- Ziegler EA, Hohlweg-Majert B, Maurer J, Mann WJ. Epidemiological data of patients with suddenhearing loss – a retrospective study over a period of three years. Laryngorhinootol. 2003;82(1):4–8. - PubMed
LinkOut - more resources
Full Text Sources